(Q33708863)

28 July 2017

7 references

1 August 2019

20 November 2019

27 November 2019

14 November 2020

13 December 2020

1 February 2021

28 October 2022

Does safety make a difference in selecting the right TNF antagonist? (English)

1 reference

disease-modifying antirheumatic drug

28 July 2017

main subject

tumor necrosis factor

2 references

1 August 2019

1 February 2021

1 reference

20 November 2019

1 reference

27 November 2019

1 reference

14 November 2020

1 reference

13 December 2020

Roy Fleischmann

1

1 reference

28 July 2017

David Yocum

series ordinal

2

1 reference

28 July 2017

publication date

21 June 2004

8 references

Arthritis Research and Therapy

28 July 2017

1 August 2019

20 November 2019

27 November 2019

14 November 2020

13 December 2020

1 February 2021

28 October 2022

8 references

28 July 2017

1 August 2019

20 November 2019

27 November 2019

14 November 2020

13 December 2020

1 February 2021

28 October 2022

6 Suppl 2

1 reference

28 July 2017

page(s)

S12-8

1 reference

https://scigraph.springernature.com/pub.10.1186/ar995

28 July 2017

exact match

0 references

cites work

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Predictors of infection in rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Progress in the treatment of rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Human immune response to recombinant human proteins

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Therapeutic monoclonal antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Review article: safety of infliximab in clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Taming TNF: strategies to restrain this proinflammatory cytokine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight–week randomized, double-blind trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833460

The incidence of cancer associated with the treatment of rheumatoid arthritis

21 June 2018

1 reference

12 December 2020

Risk of malignancy among patients with rheumatic conditions

1 reference

12 December 2020

Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis

1 reference

12 December 2020

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

The incidence and management of infusion reactions to infliximab: a large center experience

1 reference

12 December 2020

Incidence of Cancer Among Patients With Rheumatoid Arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1186/AR995

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference